___

• 1. United Nations Office on Drugs and Crime. World Drug Report. New York, USA: United Nation, 2007.
• 2. Davoli M, Bargagli AM, Perucci CA, Schifano P, Belleudi V, Hickman M, Salamina G, Diecidue R, Vigna-Taglianti F, Faggiano F, VEdeTTE Study Group. Risk of fatal overdose during and after specialist drug treatment: the VEdeTTE study, a national multi-site prospective cohort study. Addiction 2007; 102:1954-1959.
• 3. Hulse G, English D, Milne E, Holman C. The quantification of mortality resulting from the regular use of illicit opiates. Addiction 1999; 94:221-229.
• 4. Darke S, Ross J. Suicide among heroin users: rates, risk factors and methods. Addiction 2002; 97: 1383-1394.
• 5. Maxwell JC, Pullum TW, Tannert K. Deaths of clients in methadone treatment in Texas: 1994-2002. Drug Alcohol Depend 2005; 78:73-81.
• 6. McLellan AT, Arndt IO, Metzger DS, Woody GE, O’Brien CP. The effects of psychosocial services in substance abuse treatment. JAMA 1993; 269:1953-1959.
• 7. Hser Y, Hoffman V, Grella C, Anglin MD. A 33-year follow-up of narcotic addicts. Arch Gen Psychiatry 2001; 58:503-508.
• 8. Volkow ND, Li TK. Drugs and alcohol: treating and preventing abuse, addiction and their medical consequences. Pharmacol Ther 2005; 108:3-17.
• 9. Holmstrand J, Anggard E, Gunne LM. Methadone maintenance: Plasma levels and therapeutic outcome. Clin Pharmacol Ther 1978; 23:175-180.
• 10. Dyer KR, Foster DJ, White JM, Somogyi AA, Menelaou A, Bochner F. Steady-state pharmacokinetics and pharmacodynamics in methadone maintenance patients: comparison of those who do and do not experience withdrawal and concentration-effect relationships. Clin Pharmacol Ther 1999; 65:685-694.
• 11. Zhang Z, Friedmann PD, Gerstein DR. Does retention matter? Treatment duration and improvement in drug use. Addiction 2003; 98:673-684.
• 12. Milby JB. Methadone maintenance to abstinence: how many make it? J Nerv Ment Dis 1988; 176:409-422.
• 13. McLellan AT, McKay JR, Forman R, Cacciola J, Kemp J. Reconsidering the evaluation of addiction treatment: from retrospective follow-up to concurrent recovery monitoring. Addiction 2005; 100: 447-458.
• 14. Fudala PJ, Jaffe JH, Dax E, Johnson RE. Use of buprenorphine in the treatment of opioid addiction. II. Physiologic and behavioural effects of daily and alternate-day administration and abrupt withdrawal. Clin Pharmacol Ther 1990; 47; 525-534.
• 15. Hand CW, Sear JW, Uppington J, Ball MJ, McQuay HJ, Moore RA. Buprenorphine disposition in patients with renal impairment: Single and continuous dosing, with special reference to metabolites. Br J Anaesth 1990; 64;276-282.
• 16. Walsh SL, Eissenberg T. The clinical pharmacology of buprenorphine: extrapolating from the laboratory to the clinic. Drug Alcohol Depend 2003; 70:13-27.
• 17. Auriacombe M, Franques P, Tignol J. Deaths attributable to methadone vs buprenorphine in France. JAMA 2001; 285:45.
• 18. Bell J, Butler B, Lawrance A, Batey R, Salmelainen P. Comparing overdose mortality associated with methadone and buprenorphine treatment. Drug Alcohol Depend 2009; 104:73-77.
• 19. Petitjean S, Stohler R, Deglon JJ, Livoti S, Waldvogel D, Uehlinger C, Ladewig D. Double-blind randomized trial of buprenorphine and methadone in opiate dependence. Drug Alcohol Depend 2001; 62:97-104.
• 20. Greenwald MK, Johanson C, Moody DE, Woods JH, Kilbourn MR, Koeppe RA, Schuster CR, Zubieta J. Effects of buprenorphine maintenance dose on mu-opioid receptor availability, plasma concentrations, and antagonist blockade in heroin-dependent volunteers. Neuropsychopharmacol 2003; 28:2000-2009.
• 21. Mattick, RP, Kimber J, Breen C, Davoli M. Buprenorphine maintenance versus placebo or methadone maintenance for opioid dependence. The Cochrane Library, 2008.
• 22. Bell J, Dru A, Fischer B, Levit S, Sarfraz MA. Substitution therapy for heroin addiction. Subst Use Misuse 2002; 37:1145-1174.
• 23. Romelsjo A, Engdahl B, Stenbacka M, Fugelstad A, Davstad I, Leifman A, Thiblin I. Were the changes to Sweden’s maintenance treatment policy 2000-06 related to changes in opiate-related mortality and morbidity? Addiction 2010; 105:1625-1632.
• 24. Kintz P. Deaths involving buprenorphine: a compendium of French cases. Forensic Sci Int 2001; 121:65-69
• 25. Sze-Ming Chua, Tih-Shih Lee. Abuse of prescription buprenorphine, regulatory controls and the role of the primary physician. Ann Acad Med Singapore 2006; 35:492-495.
• 26. Vidal Trecan G, Varescon I, Nabet N, Boissonnas A. Intravenous use of prescribed sublingual buprenorphine tablets by drug users receiving maintenance therapy in France. Drug Alcohol Depend 2003; 69:175-181.
• 27. Bouchez J, Vignau J. The French experience – the pharmacist, general practitioner and patient perspective. Eur Addict Res 1998; 4(Suppl.1); 19-23.
• 28. Cleaver H. Georgian drug misusers switch to Western heroin substitute. BMJ 2007; 334:821.
• 29. Jaffe J, O’Keeffe C. From morphine clinics to buprenorphine; regulating opioid agonist treatment of addiction in the United States. Drug Alcohol Depend 2003; 70:3-11.
• 30. Bell J. The global diversion of pharmaceutical drugs. Opiate treatment and the diversion of pharmaceutical opiates: a clinician’s perspective. Addiction 2010; 105:1531-1537.
• 31. Bruce RD, Govindasamy S, Sylla L, Kamarulzaman A, Altice FL. Lack of reduction in buprenorphine injection after introduction of co-formulated buprenorphine/naloxone to the Malaysian market. Am J Drug Alcohol Abuse 2009; 35:68-72.
• 32. Alho H, Sinclair D, Vuori E, Holopainen A. Abuse liability of buprenorphine-naloxone tablets in untreated IV drug users. Drug Alcohol Depend 2007; 88:75-78.
• 33. Larance B, Degenhardt L, Mattick R, O’Brien S, Lintzeris N, Bell J, Winstock A, Ali R. The diversion and injection of the pharmaceutical opioids used in opioid substitution treatment: Findings from the Australian post-marketing surveillance studies of buprenorphine-naloxone, 2006-2008. Technical report , National Drug and Alcohol Research Centre, Sydney, 2009.
• 34. Van Ameijden EJC, van den Hoek AAR, Couthino RA. Injecting risk behaviour among injecting drug users in Amsterdam, 1986-1992, and its relationship to AIDS prevention programs. Am J Public Health 1994; 84:275-281.
• 35. Moos RH. Addictive Disorders in Context: Principles and Puzzles of Effective Treatment and Recovery. Psychol Addict Behav 2003; 17:3-12.
• 36. Barau K, Thirion X, Micallef J, Chuniaud-Louche C, Bellemin B, San Marco J. Comparison of methadone and high dosage buprenorphine users in French care centres. Addiction 2001; 96:1433-1441.
• 37. Auriacombe M, Fatséas M, Dubernet J, Daulouède JP, Tignol J. French field experience with buprenorphine. Am J Addict 2004; 13(Suppl.1):17-28.
• 38. Hulse, G, Milne E, English D, Holman C. The relationship between maternal use of heroin and methadone and infant birth weight. Addiction 1997; 92:1571-1579.
• 39. Jones HE, Kaltenbach K, Heil SH, Stine SM, Coyle MG, Arria AM, O’Grady KE, Selby P, Martin PR, Fischer G. Neonatal Abstinence Syndrome after Methadone or Buprenorphine Exposure. N Engl J Med 2010; 363:2320-2331.
• 40. Kornfeld H, Manfredi L. Effectiveness of Full Agonist Opioids in Patients Stabilized on Buprenorphine Undergoing Major Surgery: A Case Series. Am J Ther 2010; 17: 523-528.
• 41. Dole VP, Nyswander M. Rehabilitation of patients on methadone programs. Proceedings of the 5th National Conference on Methadone Treatment, 1973.
• 42. Ball JC, Ross A. The effectiveness of methadone maintenance treatment: patients, programs, services and outcome. New York: Springer-Verlag, 1991.
• 43. Amato L, Minozzi S, Davoli M, Vecchi S. Psychosocial combined with agonist maintenance treatments versus agonist maintenance treatments alone for treatment of opioid dependence. Cochrane Database Syst Rev 2011; 10: CD004147.
• 44. Brands B, Blake J and Marsh, D. Impact of Methadone Program Philosophy Changes on Early Treatment Outcomes. J Addict Dis 2003; 22:3:19-38.
• 45. Gjersing L, Waal H, Caplehorn JR, Gossop M, Clausen T. Staff attitudes and the associations with treatment organisation, clinical practices and outcomes in opioid maintenance treatment. BMC Health Serv Res 2010; 10:194.
• 46. De Maeyer J, Vanderplasschen W, Camfield L, Vanheule S, Sabbe B, Broekaert E. A good quality of life under the influence of methadone: A qualitative study among opiate-dependent individuals. Int J Nurs Stud 2011; 48:1244-1257.